These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37406177)

  • 21.
    Viurcos-Sanabria R; Manjarrez-Reyna AN; Solleiro-Villavicencio H; Rizo-Téllez SA; Méndez-García LA; Viurcos-Sanabria V; González-Sanabria J; Arroyo-Valerio A; Carrillo-Ruíz JD; González-Chávez A; León-Pedroza JI; Flores-Mejía R; Rodríguez-Cortés O; Escobedo G
    Front Immunol; 2022; 13():897995. PubMed ID: 35860236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
    Stoll S; Desai S; Levit E
    Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.
    Prabhu M; Yang YJ; Johnston CD; Murphy EA; Ketas TJ; Diaz-Tapia R; Jurkiewicz M; Racine-Brzostek S; Mohammed I; Sukhu AC; Singh S; Forlenza K; Iyer S; Yee J; Eng D; Marks K; Zhao Z; Klasse PJ; Permar S; Moore JP; Riley LE
    Am J Obstet Gynecol MFM; 2023 Feb; 5(2):100796. PubMed ID: 36334723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
    Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
    PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
    Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
    Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
    Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
    Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines.
    Karabiber E; Atik Ö; Tepetam FM; Ergan B; İlki A; Karakoç Aydıner E; Özen A; Özyer F; Barış S
    Tuberk Toraks; 2023 Sep; 71(3):236-249. PubMed ID: 37740627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers.
    Borghi MO; Bombaci M; Bodio C; Lonati PA; Gobbini A; Lorenzo M; Torresani E; Dubini A; Bulgarelli I; Solari F; Pregnolato F; Bandera A; Gori A; Parati G; Abrignani S; Grifantini R; Meroni PL
    Front Immunol; 2022; 13():930074. PubMed ID: 35911726
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.